Milrinone and esmolol decrease cardiac damage after resuscitation from prolonged cardiac arrest

Acta Anaesthesiologica Scandinavica
F ZoernerEgidijus Semenas

Abstract

Long-term survival after cardiac arrest (CA) due to shock-refractory ventricular fibrillation (VF) is low. Clearly, there is a need for new pharmacological interventions in the setting of cardiopulmonary resuscitation (CPR) to improve outcome. Here, hemodynamic parameters and cardiac damage are compared between the treatment group (milrinone, esmolol and vasopressin) and controls (vasopressin only) during resuscitation from prolonged CA in piglets. A total of 26 immature male piglets were subjected to 12-min VF followed by 8-min CPR. The treatment group (n=13) received i.v. (intravenous) boluses vasopressin 0.4 U/kg, esmolol 250 μg/kg and milrinone 25 μg/kg after 13 min, followed by i.v. boluses esmolol 375 μg/kg and milrinone 25 μg/kg after 18 min and continuous esmolol 15 μg/kg/h infusion during 180 min reperfusion, whereas controls (n=13) received equal amounts of vasopressin and saline. A 200 J monophasic counter-shock was delivered to achieve resumption of spontaneous circulation (ROSC) after 8 min CPR. If ROSC was not achieved, another 200 J defibrillation and bolus vasopressin 0.4 U/kg would be administered in both groups. Direct current shocks at 360 J were applied as one shot per minute over maximally 5 min. Hemodynami...Continue Reading

References

Jun 1, 1991·American Heart Journal·P Honerjäger
Mar 1, 1994·The Annals of Thoracic Surgery·C A CaldaroneS Levitsky
Jul 1, 1996·Stroke; a Journal of Cerebral Circulation·A W PrengelA Keller
Jan 16, 2002·The Annals of Thoracic Surgery·H J GeisslerS J Allen
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
Jan 12, 2005·Archives of Internal Medicine·Koko Aung, Thwe Htay
Sep 24, 2005·Annals of the New York Academy of Sciences·Lars WiklundSamar Basu
Sep 4, 2007·Resuscitation·Daniel BourqueMarco Charneux
Nov 6, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Patricia N BanforRyan M Fryer
Sep 22, 2009·Acta Anaesthesiologica Scandinavica·E SemenasL Wiklund
Oct 20, 2010·Resuscitation·Jerry P NolanUNKNOWN ERC Guidelines Writing Group
May 18, 2011·Heart Failure Reviews·Athanasios Chalkias, Theodoros Xanthos
Jul 12, 2011·Current Opinion in Critical Care·Jerry P Nolan
Mar 20, 2012·Resuscitation·Todd M LarabeeCharles M Little
Mar 21, 2012·Critical Care : the Official Journal of the Critical Care Forum·Claudio SandroniMassimo Antonelli
Mar 14, 2013·Journal of Internal Medicine·J HollenbergM Rosenqvist
Apr 13, 2013·Acta Anaesthesiologica Scandinavica·L WiklundH S Sharma
Apr 16, 2013·Resuscitation·Rachael T FothergillMark Whitbread

❮ Previous
Next ❯

Citations

Sep 4, 2016·Resuscitation·Wulfran Bougouin, Alain Cariou
Dec 6, 2019·Intensive Care Medicine Experimental·Hilde KarlsenTheresa Mariero Olasveengen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.